Skip to content

ICH GCP E6 Revision 3 is here. Regulatory Considerations Expert Group to review

Date: June 19, 2023

The R&D industry, especially those that are working on clinical trials, have been waiting for the new release of ICH GCP E6. The 3rd revision of the Good Clinical Practice (GCP) E6 guidance has been recently published as a draft, for public review and consultation.

What is changing in E6 revision 3? E6 is undergoing a complete restructure with the aim to address the complexity, diversity and new technology deployed in modern clinical trials and will consist mainly in two different main sections. One mainly focused on ‘traditional’ interventional clinical trials (Annex 1) and the other on ‘non-traditional’ clinical trials, to include designs such as pragmatic and decentralized clinical trials (Annex 2).

The ACDM Regulatory Considerations Expert Group is going to initiate a thorough review of this new draft guidance, to assess how new recommendations will impact on clinical trials and on any activities where data management is directly or indirectly involved.

If you are interested in knowing more about this new ICH GCP guidance, and would like to be involved in this new challenge across the clinical trials environment, please reach out to the ACDM group or DMEG chair, Silvia Perez-Torres: https://lnkd.in/dCRGK5T%20 

 


 

Explore More News

AI model trained on de-identified data from 57 million people

Researchers at UCL have trained an AI model using de-identified data from 57 million . . .

Read More

ACDM Regulatory Considerations DMEG Update: ICH E6 (R3) GCP Final Publication Released

The final publication of ICH E6 (R3) Good Clinical Practice (GCP) General Principles and . . .

Read More

ICH E6(R3) Guideline reaches Step 4 of the ICH Process

ICH E6(R3) reaches Step 4 of the ICH Process on 6th January 2025. The guideline . . .

Read More

U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties

The U.S. Food and Drug Administration has issued its first guidance on the use of . . .

Read More

ACDM DMEG News: Regulatory Updates and Forthcoming Challenges for 2025

As 2024 draws to a close, the Regulatory Considerations Data Management Expert Group . . .

Read More

Audit Trail Review DMEG Update – New Guide

The Audit Trail Review (ATR) DMEG has been hard at work putting the finishing touches on a . . .

Read More

Risk Based Quality Management DMEG Update – Recent Discussions

This year our focus has switched away from generalised RBQM to applying risk-based . . .

Read More

Regulatory Considerations DMEG Update – September 2024

The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .

Read More

Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)

This article has been submitted by Leeni Joshua of ICON plc Introduction: Digital Data . . .

Read More

Guidance for Industry: Conducting Clinical Trials With Decentralized Elements

The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .

Read More

Welcome FGK Clinical Research as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .

Read More

Welcome LINK Medical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome LINK Medical as . . .

Read More